In the US today, 1 in 3, or 23 million eligible people are not screened for colorectal cancer. 

As a consequence, 60% of CRC cases are diagnosed when the cancer has already spread regionally or to distant organs and treatment becomes more challenging. 

For those people who have been offered, and have a history of not completing screening by guideline recommended methods, Epi proColon offers an acceptable test option that may improve participation in CRC screening programs. The availability of a blood test option may augment the efforts of the American Cancer Society and other organizations in meeting the target goal of reaching 80% of eligible Americans up to date for screening by 2018.